Difference between revisions of "Inherited coagulopathy"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "6 PubMed" to "6/ PubMed")
m (Text replacement - "*<big>We have moved How I Treat articles to a dedicated page.</big>" to "*''We have moved How I Treat articles to a dedicated page.''")
 
(19 intermediate revisions by 3 users not shown)
Line 3: Line 3:
 
[[#top|Back to Top]]
 
[[#top|Back to Top]]
 
</div>
 
</div>
−
{{#lst:Section editor transclusions|heme}}
+
{{#lst:Editorial board transclusions|heme}}
 +
*''We have moved [[How I Treat]] articles to a dedicated page.''
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-
−
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
+
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
−
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
+
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 
|}
 
|}
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
 
=Guidelines=
 
=Guidelines=
 +
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
 
==ASH/ISTH/NHF/WFH==
 
==ASH/ISTH/NHF/WFH==
−
*'''2021:''' James et al. [https://doi.org/10.1182/bloodadvances.2020003265 ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease]
+
*'''2021:''' James et al. [https://doi.org/10.1182/bloodadvances.2020003265 ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease] [https://www.ncbi.nlm.nih.gov/pubmed/33570651 PubMed]
−
*'''2021:''' Connell et al. [https://doi.org/10.1182/bloodadvances.2020003264 ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease]
+
*'''2021:''' Connell et al. [https://doi.org/10.1182/bloodadvances.2020003264 ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease] [https://www.ncbi.nlm.nih.gov/pubmed/33570647 PubMed]
 +
 
 
==BSH==
 
==BSH==
−
*'''2020:''' Rayment et al. [https://doi.org/10.1111/bjh.16704 Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B]
+
*'''2020:''' Rayment et al. [https://doi.org/10.1111/bjh.16704 Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B] [https://www.ncbi.nlm.nih.gov/pubmed/32390158 PubMed]
−
=="How I treat"==
 
−
*'''2020:''' Leebeek et al. [https://doi.org/10.1182/blood.2019000964 How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease]
 
−
*'''2019:''' Young. [https://doi.org/10.1111/bjh.15942 How I treat children with haemophilia and inhibitors]
 
−
*'''2019:''' Lavin & O'Donnell [https://doi.org/10.1182/blood-2018-10-844936 How I treat low von Willebrand factor levels]
 
  
 
=Factor VIII deficiency (Hemophilia A), replacement products=
 
=Factor VIII deficiency (Hemophilia A), replacement products=
Line 35: Line 34:
 
|[https://doi.org/10.1056/NEJMoa1803550 Mahlangu et al. 2018 (HAVEN 3)]
 
|[https://doi.org/10.1056/NEJMoa1803550 Mahlangu et al. 2018 (HAVEN 3)]
 
|style="background-color:#1a9851"|Phase 3 (E-esc)
 
|style="background-color:#1a9851"|Phase 3 (E-esc)
−
|[[#Observation_88|No prophylaxis]]
+
|[[#Observation_888|No prophylaxis]]
−
|style="background-color:#1a9850"|Lower bleeding rate
+
|style="background-color:#1a9850"|Lower bleeding rate (primary endpoint)
 +
|-
 +
|[https://doi.org/10.1016/S2352-3026(22)00377-5 Negrier et al. 2023 (HAVEN 6)]
 +
| style="background-color:#91cf61" |Non-randomized phase 3
 +
| style="background-color:#d3d3d3" |
 +
| style="background-color:#d3d3d3" |
 
|-
 
|-
 
|}
 
|}
Line 44: Line 48:
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
# '''HAVEN 3:''' Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, Schmitt C, Jiménez-Yuste V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy GG, Kruse-Jarres R. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018 Aug 30;379(9):811-822. [https://doi.org/10.1056/NEJMoa1803550 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30157389 PubMed]
+
# '''HAVEN 3:''' Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, Schmitt C, Jiménez-Yuste V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy GG, Kruse-Jarres R. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018 Aug 30;379(9):811-822. [https://doi.org/10.1056/NEJMoa1803550 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30157389/ PubMed] [https://clinicaltrials.gov/study/NCT02847637 NCT02847637]
 +
#'''HAVEN 6:''' Negrier C, Mahlangu J, Lehle M, Chowdary P, Catalani O, Bernardi RJ, Jimenez-Yuste V, Beckermann BM, Schmitt C, Ventriglia G, Windyga J, d'Oiron R, Moorehead P, Koparkar S, Teodoro V, Shapiro AD, Oldenburg J, Hermans C. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Lancet Haematol. 2023 Mar;10(3):e168-e177. Epub 2023 Jan 27. [https://doi.org/10.1016/S2352-3026(22)00377-5 link to original article] [https://pubmed.ncbi.nlm.nih.gov/36716761/ PubMed] [https://clinicaltrials.gov/study/NCT04158648 NCT04158648]
 +
 
 
=Factor VIII deficiency (Hemophilia A), with inhibitors, all lines of therapy=
 
=Factor VIII deficiency (Hemophilia A), with inhibitors, all lines of therapy=
 
==Emicizumab monotherapy {{#subobject:f198c0|Regimen=1}}==
 
==Emicizumab monotherapy {{#subobject:f198c0|Regimen=1}}==
Line 57: Line 63:
 
|[https://doi.org/10.1056/NEJMoa1703068 Oldenburg et al. 2017 (HAVEN 1)]
 
|[https://doi.org/10.1056/NEJMoa1703068 Oldenburg et al. 2017 (HAVEN 1)]
 
|style="background-color:#1a9851"|Phase 3 (E-esc)
 
|style="background-color:#1a9851"|Phase 3 (E-esc)
−
|[[#Observation_88|No prophylaxis]]
+
|[[#Observation_888|No prophylaxis]]
−
|style="background-color:#1a9850"|Lower bleeding rate
+
|style="background-color:#1a9850"|Lower bleeding rate (primary endpoint)
 
|-
 
|-
 
|}
 
|}
Line 66: Line 72:
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
# '''HAVEN 1:''' Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017 Aug 31;377(9):809-818. Epub 2017 Jul 10. [https://doi.org/10.1056/NEJMoa1703068 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28691557 PubMed]
+
# '''HAVEN 1:''' Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017 Aug 31;377(9):809-818. Epub 2017 Jul 10. [https://doi.org/10.1056/NEJMoa1703068 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28691557/ PubMed]
 
# '''HAVEN 2:''' Young G, Liesner R, Chang T, Sidonio R, Oldenburg J, Jiménez-Yuste V, Mahlangu J, Kruse-Jarres R, Wang M, Uguen M, Doral MY, Wright LY, Schmitt C, Levy GG, Shima M, Mancuso ME. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019 Dec 12;134(24):2127-2138. [https://doi.org/10.1182/blood.2019001869 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31697801/ PubMed]
 
# '''HAVEN 2:''' Young G, Liesner R, Chang T, Sidonio R, Oldenburg J, Jiménez-Yuste V, Mahlangu J, Kruse-Jarres R, Wang M, Uguen M, Doral MY, Wright LY, Schmitt C, Levy GG, Shima M, Mancuso ME. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019 Dec 12;134(24):2127-2138. [https://doi.org/10.1182/blood.2019001869 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31697801/ PubMed]
 
==Rituximab monotherapy {{#subobject:6d79c2|Regimen=1}}==
 
==Rituximab monotherapy {{#subobject:6d79c2|Regimen=1}}==
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:3f9925|Variant=1}}===
 
===Regimen {{#subobject:3f9925|Variant=1}}===
−
{| class="wikitable" style="width: 40%; text-align:center;"  
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
−
!style="width: 25%"|Study
+
!style="width: 33%"|Study
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5726888/ Leissinger et al. 2014]
+
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5726888/ Leissinger et al. 2014 (RICH)]
 +
|2006-08 to 2010-11
 
|style="background-color:#91cf61"|Phase 2
 
|style="background-color:#91cf61"|Phase 2
 
|-
 
|-
Line 81: Line 89:
 
<div class="toccolours" style="background-color:#b3e2cd">
 
<div class="toccolours" style="background-color:#b3e2cd">
 
====Immunosuppressive therapy====
 
====Immunosuppressive therapy====
−
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22
+
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
−
'''28-day course'''
+
'''7-day cycle for 4 cycles (28-day course)'''
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
# Kempton CL, Allen G, Hord J, Kruse-Jarres R, Pruthi RK, Walsh C, Young G, Soucie JM. Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A. Am J Hematol. 2012 Sep;87(9):933-6. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645919/ link to PMC article] '''does not contain dosing details''' [https://pubmed.ncbi.nlm.nih.gov/22733686/ PubMed]
+
# Kempton CL, Allen G, Hord J, Kruse-Jarres R, Pruthi RK, Walsh C, Young G, Soucie JM. Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A. Am J Hematol. 2012 Sep;87(9):933-6. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645919/ link to PMC article] '''does not contain dosing details''' [https://pubmed.ncbi.nlm.nih.gov/22733686/ PubMed]
−
# Leissinger C, Josephson CD, Granger S, Konkle BA, Kruse-Jarres R, Ragni MV, Journeycake JM, Valentino L, Key NS, Gill JC, McCrae KR, Neufeld EJ, Manno C, Raffini L, Saxena K, Torres M, Marder V, Bennett CM, Assmann SF. Rituximab for treatment of inhibitors in haemophilia A: a phase II study. Thromb Haemost. 2014 Sep 2;112(3):445-58. [https://doi.org/10.1160/TH14-01-0078 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5726888/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24919980/ PubMed]
+
# '''RICH:''' Leissinger C, Josephson CD, Granger S, Konkle BA, Kruse-Jarres R, Ragni MV, Journeycake JM, Valentino L, Key NS, Gill JC, McCrae KR, Neufeld EJ, Manno C, Raffini L, Saxena K, Torres M, Marder V, Bennett CM, Assmann SF. Rituximab for treatment of inhibitors in haemophilia A: a phase II study. Thromb Haemost. 2014 Sep 2;112(3):445-58. Epub 2014 Jun 12. [https://doi.org/10.1160/TH14-01-0078 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5726888/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/24919980/ PubMed] [https://clinicaltrials.gov/study/NCT00331006 NCT00331006]
 +
 
 
=Factor IX deficiency (Hemophilia B), all lines of therapy=
 
=Factor IX deficiency (Hemophilia B), all lines of therapy=
 
To be completed
 
To be completed
Line 92: Line 101:
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
 
[[Category:Bleeding disorders]]
 
[[Category:Bleeding disorders]]
−
[[Category:Clinical pharmacology]]
 

Latest revision as of 11:34, 15 May 2024

Back to Top

Section editor
Tillman Benjamin-2.jpg
 Benjamin Tillman, MD
Vanderbilt University
Nashville, TN, USA
LinkedIn
  • We have moved How I Treat articles to a dedicated page.
3 regimens on this page
3 variants on this page


Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

ASH/ISTH/NHF/WFH

BSH

Factor VIII deficiency (Hemophilia A), replacement products

To be completed

Factor VIII deficiency (Hemophilia A), without inhibitors, all lines of therapy

Emicizumab monotherapy

Regimen

Study Evidence Comparator Comparative Efficacy
Mahlangu et al. 2018 (HAVEN 3) Phase 3 (E-esc) No prophylaxis Lower bleeding rate (primary endpoint)
Negrier et al. 2023 (HAVEN 6) Non-randomized phase 3

Supportive therapy

References

  1. HAVEN 3: Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, Schmitt C, Jiménez-Yuste V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy GG, Kruse-Jarres R. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018 Aug 30;379(9):811-822. link to original article PubMed NCT02847637
  2. HAVEN 6: Negrier C, Mahlangu J, Lehle M, Chowdary P, Catalani O, Bernardi RJ, Jimenez-Yuste V, Beckermann BM, Schmitt C, Ventriglia G, Windyga J, d'Oiron R, Moorehead P, Koparkar S, Teodoro V, Shapiro AD, Oldenburg J, Hermans C. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Lancet Haematol. 2023 Mar;10(3):e168-e177. Epub 2023 Jan 27. link to original article PubMed NCT04158648

Factor VIII deficiency (Hemophilia A), with inhibitors, all lines of therapy

Emicizumab monotherapy

Regimen

Study Evidence Comparator Comparative Efficacy
Oldenburg et al. 2017 (HAVEN 1) Phase 3 (E-esc) No prophylaxis Lower bleeding rate (primary endpoint)

Supportive therapy

References

  1. HAVEN 1: Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017 Aug 31;377(9):809-818. Epub 2017 Jul 10. link to original article PubMed
  2. HAVEN 2: Young G, Liesner R, Chang T, Sidonio R, Oldenburg J, Jiménez-Yuste V, Mahlangu J, Kruse-Jarres R, Wang M, Uguen M, Doral MY, Wright LY, Schmitt C, Levy GG, Shima M, Mancuso ME. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019 Dec 12;134(24):2127-2138. link to original article PubMed

Rituximab monotherapy

Regimen

Study Dates of enrollment Evidence
Leissinger et al. 2014 (RICH) 2006-08 to 2010-11 Phase 2

Immunosuppressive therapy

7-day cycle for 4 cycles (28-day course)

References

  1. Kempton CL, Allen G, Hord J, Kruse-Jarres R, Pruthi RK, Walsh C, Young G, Soucie JM. Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A. Am J Hematol. 2012 Sep;87(9):933-6. link to PMC article does not contain dosing details PubMed
  2. RICH: Leissinger C, Josephson CD, Granger S, Konkle BA, Kruse-Jarres R, Ragni MV, Journeycake JM, Valentino L, Key NS, Gill JC, McCrae KR, Neufeld EJ, Manno C, Raffini L, Saxena K, Torres M, Marder V, Bennett CM, Assmann SF. Rituximab for treatment of inhibitors in haemophilia A: a phase II study. Thromb Haemost. 2014 Sep 2;112(3):445-58. Epub 2014 Jun 12. link to original article link to PMC article contains dosing details in manuscript PubMed NCT00331006

Factor IX deficiency (Hemophilia B), all lines of therapy

To be completed

Retrieved from "https://hemonc.org/w/index.php?title=Inherited_coagulopathy&oldid=85689"